Navigating the Rapidly Changing Landscape of EoE Treatment
Includes a Live Web Event on 09/18/2024 at 8:00 PM (EDT)
-
Register
- Non-member - Free!
- Member - Free!
The last two years have seen rapid advancement in therapy options for EoE, moving beyond dietary elimination, off-label use of proton pump inhibitors and swallowed topical steroids. In May of 2022, dupilumab became the first FDA approved medication for EoE in patients 12 years and older, and January 2024 brought approval for ages 1-11. Next came the first and only oral medication approved for EoE - budesonide oral suspension EOHILIA. These changes have resulted in questions around best approaches and practices in treating EoE patients. Our webinar will deliver a particular focus on new medication options for pediatric patients with EoE as well as challenges faced by clinicians and patients.
Rajitha D. Venkatesh, MD, MPH (Moderator)
Co-Director, Eosinophilic GI Disorders Program, Nationwide Children’s Hospital
Assistant Professor of Clinical Pediatrics, The Ohio State University College of Medicine
Erin P. Syverson, MD
Director, Eosinophilic Gastrointestinal Disease Program
Attending Physician, Division of Gastroenterology, Hepatology, & Nutrition, Boston Children's Hospital
Ben Kuhn, DO
Division Chief, Pediatric Gastroenterology Director, MUSC Children’s Center for Eosinophilic Disorders
Professor of Pediatrics Medical University of South Carolina
Calies Menard-Katcher, MD MSCs
Associate Professor of Pediatrics Research Director, Digestive Health Institute | Associate Director for Clinical Research, Gastrointestinal Eosinophilic Diseases Program Children’s Hospital Colorado
Division of Gastroenterology Hepatology and Nutrition Department of Pediatrics, University of Colorado School of Medicine
Complete
Next
Failed
Available
Locked